Name: Name:3-[(1S)-1-(Dimethylaminoethyl)]phenol
Brand: Angene
SKU: AG001AQC
Rating: 90 (10 reviews)

Catalog Number:

AG001AQC

Chemical Name:

3-[(1S)-1-(Dimethylaminoethyl)]phenol

CAS Number:

139306-10-8

Molecular Formula:

C10H15NO

Molecular Weight:

165.2322

MDL Number:

MFCD06656491

IUPAC Name:

3-[(1S)-1-(dimethylamino)ethyl]phenol

InChI:

InChI=1S/C10H15NO/c1-8(11(2)3)9-5-4-6-10(12)7-9/h4-8,12H,1-3H3/t8-/m0/s1

InChI Key:

GQZXRLWUYONVCP-QMMMGPOBSA-N

SMILES:

CN([C@H](c1cccc(c1)O)C)C

EC Number:

478-670-2

UNII:

1608PLR9ZO

Complexity:

136

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

165.115g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

165.236g/mol

Monoisotopic Mass:

165.115g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

23.5A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

1.8

Title	Journal
Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.	Journal of pharmaceutical and biomedical analysis 20120501
Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients.	Journal of Alzheimer's disease : JAD 20120101
Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product.	Drug testing and analysis 20100501
Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.	Electrophoresis 20090201
Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.	Journal of clinical pharmacology 20080201
Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.	Clinical pharmacology and therapeutics 20080101
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.	Clinical drug investigation 20080101
A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.	Rapid communications in mass spectrometry : RCM 20060101
A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry.	Biomedical chromatography : BMC 20040401
Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.	Biochemistry 20020319